太平洋生物科学

最新新闻

• 评级变动
  TR | OpenAI - 4o Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $1.5
  \u5e02\u573a\u8d44\u8baf · 2025/8/24
• 评级变动
  Morgan Stanley Initiates Pacific Biosciences of California(PACB.US) With Hold Rating, Announces Target Price $2
  \u5e02\u573a\u8d44\u8baf · 2025/8/11
• Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  A Quick Look at Today's Ratings for Pacific Biosciences of California(PACB.US), With a Forecast Between $2 to $3
  \u5e02\u573a\u8d44\u8baf · 2025/5/10
• TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Biodesix (BDSX), Pacific Biosciences (PACB) and Odyssey Therapeutics, Inc. (ODTX)
  TipRanks · 2026/8/6
• 评级变动
  Analysts Are Bullish on Top Healthcare Stocks: Pacific Biosciences (PACB), 20/20 Biolabs, Inc. (AIDX)
  TipRanks · 2026/5/9
• CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• CCORF Maintains Pacific Biosciences of California(PACB.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/11
• 评级变动
  Stephens Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Cuts Target Price to $2
  \u5e02\u573a\u8d44\u8baf · 2025/11/10
• 评级变动
  Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $2
  \u5e02\u573a\u8d44\u8baf · 2025/11/11
• 评级变动
  Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Cuts Target Price to $1
  \u5e02\u573a\u8d44\u8baf · 2026/4/14
• 评级变动
  Bernstein Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Raises Target Price to $1.7
  \u5e02\u573a\u8d44\u8baf · 2025/8/8
• 评级变动
  Piper Sandler Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Cuts Target Price to $1.25
  \u5e02\u573a\u8d44\u8baf · 2025/5/16
• 评级变动
  Morgan Stanley Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
  \u5e02\u573a\u8d44\u8baf · 2025/5/28
• 评级变动
  Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $2
  \u5e02\u573a\u8d44\u8baf · 2025/4/10
• Barclays Maintains Pacific Biosciences of California(PACB.US) With Sell Rating, Maintains Target Price $1.25
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Scotiabank Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $2
  \u5e02\u573a\u8d44\u8baf · 2025/4/11
• 评级变动
  Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Maintains Target Price $1.5
  \u5e02\u573a\u8d44\u8baf · 2025/10/3
• 评级变动
  Barclays Maintains Pacific Biosciences of California(PACB.US) With Hold Rating, Raises Target Price to $2
  \u5e02\u573a\u8d44\u8baf · 2026/2/13

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。